J
James E. Udelson
Researcher at Tufts Medical Center
Publications - 407
Citations - 43252
James E. Udelson is an academic researcher from Tufts Medical Center. The author has contributed to research in topics: Heart failure & Coronary artery disease. The author has an hindex of 93, co-authored 387 publications receiving 38834 citations. Previous affiliations of James E. Udelson include University of Minnesota & American College of Cardiology.
Papers
More filters
Journal ArticleDOI
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Bernard J. Gersh,Barry J. Maron,Robert O. Bonow,Joseph A. Dearani,Joseph A. Dearani,Michael A. Fifer,Mark S. Link,Srihari S. Naidu,Rick A. Nishimura,Steve R. Ommen,Harry Rakowski,Christine E. Seidman,Jeffrey A. Towbin,James E. Udelson,Clyde W. Yancy +14 more
TL;DR: This information is current as of May 14, 2012 and located on the World Wide Web at: http://content.onlinejacc.org/cgi/content/full/58/25/2703.
Journal ArticleDOI
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Marvin A. Konstam,Mihai Gheorghiade,John C. Burnett,Liliana Grinfeld,Aldo P. Maggioni,Karl Swedberg,James E. Udelson,Faiez Zannad,Thomas D. Cook,John Ouyang,Christopher Zimmer,Cesare Orlandi +11 more
TL;DR: Tolvaptan initiated for acute treatment of patients hospitalized with heart failure had no effect on long-term mortality or heart failure-related morbidity.
Journal ArticleDOI
ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)
Francis J. Klocke,Michael G. Baird,Beverly H. Lorell,Timothy M. Bateman,Joseph V. Messer,Daniel S. Berman,Patrick T. O'Gara,Blase A. Carabello,Richard O. Russell,Manuel D. Cerqueira,Martin St. John Sutton,Anthony N. DeMaria,James E. Udelson,J. Ward Kennedy,Mario S. Verani,Kim A. Williams,Elliott M. Antman,Sidney C. Smith,Joseph S. Alpert,Gabriel Gregoratos,Jeffrey L. Anderson,Loren F. Hiratzka,David P. Faxon,Sharon A. Hunt,Valentin Fuster,Alice K. Jacobs,Raymond J. Gibbons +26 more
TL;DR: The American College of Cardiology/AHA Task Force on Practice Guidelines regularly reviews existing guidelines to determine when an update or full revision is needed.
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure
Marvin A. Konstam,Mihai Gheorghiade,John C. Burnett,Liliana Grinfeld,Aldo P. Maggioni,Karl Swedberg,James E. Udelson,Faiez Zannad,John Ouyang,Christopher Zimmer,Cesare Orlandi +10 more
Abstract: CONTEXT
Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure.
OBJECTIVE
To investigate the effects of tolvaptan initiated in patients hospitalized with heart failure.
DESIGN, SETTING, AND PARTICIPANTS
The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study. The outcome trial comprised 4133 patients within 2 short-term clinical status studies, who were hospitalized with heart failure, randomized at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006, and followed up during long-term treatment.
INTERVENTION
Within 48 hours of admission, patients were randomly assigned to receive oral tolvaptan, 30 mg once per day (n = 2072), or placebo (n = 2061) for a minimum of 60 days, in addition to standard therapy.
MAIN OUTCOME MEASURES
Dual primary end points were all-cause mortality (superiority and noninferiority) and cardiovascular death or hospitalization for heart failure (superiority only). Secondary end points included changes in dyspnea, body weight, and edema.
RESULTS
During a median follow-up of 9.9 months, 537 patients (25.9%) in the tolvaptan group and 543 (26.3%) in the placebo group died (hazard ratio, 0.98; 95% confidence interval [CI], 0.87-1.11; P = .68). The upper confidence limit for the mortality difference was within the prespecified noninferiority margin of 1.25 (P<.001). The composite of cardiovascular death or hospitalization for heart failure occurred in 871 tolvaptan group patients (42.0%) and 829 placebo group patients (40.2%; hazard ratio, 1.04; 95% CI, 0.95-1.14; P = .55). Secondary end points of cardiovascular mortality, cardiovascular death or hospitalization, and worsening heart failure were also not different. Tolvaptan significantly improved secondary end points of day 1 patient-assessed dyspnea, day 1 body weight, and day 7 edema. In patients with hyponatremia, serum sodium levels significantly increased. The Kansas City Cardiomyopathy Questionnaire overall summary score was not improved at outpatient week 1, but body weight and serum sodium effects persisted long after discharge. Tolvaptan caused increased thirst and dry mouth, but frequencies of major adverse events were similar in the 2 groups.
CONCLUSION
Tolvaptan initiated for acute treatment of patients hospitalized with heart failure had no effect on long-term mortality or heart failure-related morbidity.
TRIAL REGISTRATION
clinicaltrials.gov Identifier: NCT00071331
Journal ArticleDOI
Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.
TL;DR: A strong association between myocardial viability on noninvasive testing and improved survival after revascularization in patients with chronic CAD and LV dysfunction is demonstrated.